182 related articles for article (PubMed ID: 24070820)
1. Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection.
Reitsma JM; Terhune SS
Antiviral Res; 2013 Nov; 100(2):321-7. PubMed ID: 24070820
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
3. Antagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection.
Bigley TM; Reitsma JM; Terhune SS
J Virol; 2015 Oct; 89(20):10230-46. PubMed ID: 26223645
[TBL] [Abstract][Full Text] [Related]
4. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.
Webel R; Hakki M; Prichard MN; Rawlinson WD; Marschall M; Chou S
J Virol; 2014 May; 88(9):4776-85. PubMed ID: 24522923
[TBL] [Abstract][Full Text] [Related]
5. Impact of RNA polymerase I inhibitor CX-5461 on viral kinase-dependent and -independent cytomegalovirus replication.
Westdorp KN; Terhune SS
Antiviral Res; 2018 May; 153():33-38. PubMed ID: 29458130
[TBL] [Abstract][Full Text] [Related]
6. Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection.
Hakki M; Drummond C; Houser B; Marousek G; Chou S
Antiviral Res; 2011 Nov; 92(2):313-8. PubMed ID: 21906628
[TBL] [Abstract][Full Text] [Related]
7. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
Chou S
Antimicrob Agents Chemother; 2009 Jan; 53(1):81-5. PubMed ID: 18981262
[TBL] [Abstract][Full Text] [Related]
8. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.
Schubert A; Ehlert K; Schuler-Luettmann S; Gentner E; Mertens T; Michel D
BMC Infect Dis; 2013 Jul; 13():330. PubMed ID: 23870704
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
Chou S
Rev Med Virol; 2008; 18(4):233-46. PubMed ID: 18383425
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.
Chou S; Wechel LC; Marousek GI
J Infect Dis; 2007 Jul; 196(1):91-4. PubMed ID: 17538888
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
[TBL] [Abstract][Full Text] [Related]
12. Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir.
McGregor A; Choi KY; Cui X; McVoy MA; Schleiss MR
Antiviral Res; 2008 Jun; 78(3):250-9. PubMed ID: 18325607
[TBL] [Abstract][Full Text] [Related]
13. Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest.
Reitsma JM; Savaryn JP; Faust K; Sato H; Halligan BD; Terhune SS
Cell Host Microbe; 2011 Feb; 9(2):103-14. PubMed ID: 21320693
[TBL] [Abstract][Full Text] [Related]
14. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.
Selleseth DW; Talarico CL; Miller T; Lutz MW; Biron KK; Harvey RJ
Antimicrob Agents Chemother; 2003 Apr; 47(4):1468-71. PubMed ID: 12654696
[TBL] [Abstract][Full Text] [Related]
15. Maribavir use in practice for cytomegalovirus infection in French transplantation centers.
Alain S; Revest M; Veyer D; Essig M; Rerolles JP; Rawlinson W; Mengelle C; Huynh A; Kamar N; Garrigue I; Kaminski H; Segard C; Presne C; Mazeron MC; Avettant-Fenoël V; Lecuit M; Lortholary O; Coaquette A; Hantz S; Leruez-Ville M; Ploy MC
Transplant Proc; 2013 May; 45(4):1603-7. PubMed ID: 23726629
[TBL] [Abstract][Full Text] [Related]
16. Impact of a cytomegalovirus kinase inhibitor on infection and neuronal progenitor cell differentiation.
Bigley TM; McGivern JV; Ebert AD; Terhune SS
Antiviral Res; 2016 May; 129():67-73. PubMed ID: 26875788
[TBL] [Abstract][Full Text] [Related]
17. Human Cytomegalovirus Disruption of Calcium Signaling in Neural Progenitor Cells and Organoids.
Sison SL; O'Brien BS; Johnson AJ; Seminary ER; Terhune SS; Ebert AD
J Virol; 2019 Sep; 93(17):. PubMed ID: 31217241
[TBL] [Abstract][Full Text] [Related]
18. Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus.
Drouot E; Piret J; Boivin G
Antivir Ther; 2016; 21(6):535-539. PubMed ID: 26844400
[TBL] [Abstract][Full Text] [Related]
19. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
Drew WL; Miner RC; Marousek GI; Chou S
J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
[TBL] [Abstract][Full Text] [Related]
20. Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication.
Wang FZ; Roy D; Gershburg E; Whitehurst CB; Dittmer DP; Pagano JS
J Virol; 2009 Dec; 83(23):12108-17. PubMed ID: 19759127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
